VDA 1214Alternative Names: VDA1214
Latest Information Update: 26 May 2016
At a glance
- Originator VidacPharma
- Class Small molecules
- Mechanism of Action Keratinocyte modulators; Voltage-dependent anion channel modulators; Voltage-gated potassium channel modulators; Voltage-gated sodium channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 May 2016 Early research in Solid tumours in Israel (unspecified route) before May 2016 (VidacPharma pipeline; May 2016)